Mesoblast (ASX:MSB) announced that it has acquired an exclusive worldwide licence for a cutting-edge chimeric antigen receptor technology platform.
The acquisition, finalised through the issuance of ordinary shares, focuses on the precision-enhanced augmentation of Mesoblast's proprietary mesenchymal lineage stromal cell products.
Developed by researchers at the prestigious Mayo Clinic, the platform allows for the genetic engineering of CAR constructs into MSCs, a breakthrough designed to dramatically improve the cells' ability to home in on inflamed tissues.
By increasing target specificity, Mesoblast aims to unlock new levels of potency for treating complex inflammatory and autoimmune conditions, including ulcerative colitis and Crohn’s disease.
The integration of CAR technology represents a pivotal evolution for Mesoblast’s "off-the-shelf" cellular medicines.
Beyond gastrointestinal applications, the company plans to deploy CAR-MSC candidates expressing CD19 to target B-cell-driven autoimmune diseases like lupus nephritis.
CEO Silviu Itescu emphasised that this technology aligns perfectly with the company’s strategy to extend market leadership through superior efficacy and expanded indications.
Under the terms of the agreement, the Mayo Clinic will provide ongoing in-kind support, including GMP manufacturing assistance, to accelerate the development of these next-generation therapies.
At the time of reporting, Mesoblast's share price was $2.07.